Company Team Projects Media Contact

• 17.04.2018: Positive Topline Results from First-in-Man Trial with CAL02 in the Treatment of Severe Pneumonia

• 29.03.2018: Combioxin Announces Completion of the CAL02-001 clinical trial

• 10.10.2017: Independent Data Monitoring Committee concluded that CAL02 showed positive safety profile at high dose in the CAL02-001 clinical trial

• 20.07.2017: Combioxin appoints industry veteran Jeffrey Jump as Chairman

• 15.03.2017: Oral presentation of results from the CAL02-001 clinical trial at ECCMID 2017

• 09.08.2016: Combioxin escalates to high dose in CAL02-001 FIM clinical trial

• 23.03.2016: Combioxin announces first patient enrolled in CAL02 FIM clinical trial

• 12.01.2016: Combioxin receives Clinical Trial Authorisation for a first-in-man in patients

• 02.01.2015: Positive preclinical efficacy data for CAL02 published in Nature Biotechnology



• 15.02.2017: Discover Combioxin's CAL02 against bacterial resistance broadcasted on 3sat - Nano

• 04.11.2014: Une nouvelle voie pour lutter contre la résistance aux antibiotiques - Le Temps

• 29.10.2014 : Le long chemin vers la therapy - L'AGEFI

• 12.09.2014: Au-delà des antibiotiques - vaincre les résistances des bactérie - Le Temps